China’s Brii Biosciences (HKG: 2137) has announced the first patient dosing in a Phase I clinical study assessing the safety, tolerability, and pharmacokinetics of its BRII-297 in healthy subjects in Australia. This marks a significant step in the development of the drug candidate, which is being closely watched for its potential impact on the treatment of central nervous system disorders.
BRII-297: A Novel Long-Acting Injectable Drug Candidate
The in-house discovery, BRII-297, is a first-of-its-kind long-acting injectable (LAI) drug candidate that acts as a gamma-aminobutyric acid A (GABAA) receptor positive allosteric modulator (PAM). This mechanism of action is designed to restore “normal” levels of GABAA receptor function, which is crucial for addressing various depressive and anxiety disorders within the central nervous system.
Potential Impact on CNS Disorder Treatment
The initiation of this Phase I study is a critical milestone for Brii Biosciences as it seeks to understand the drug’s behavior in healthy subjects and pave the way for future trials involving patient populations. The study’s focus on safety, tolerability, and pharmacokinetics will provide valuable insights into the drug’s potential effectiveness and side effect profile, which are essential for determining its suitability as a treatment for CNS disorders.-Fineline Info & Tech
